Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SomatoKine. Insmed.

Peter Norman1

  • 1Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

SomatoKine, a novel therapeutic combining insulin-like growth factor-1 and its binding protein, is being investigated for growth hormone insensitivity syndrome and diabetes. Clinical trials are underway to assess its efficacy as an injectable insulin sensitizer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lived experience of depression: a bottom-up review co-written by experts by experience and academics.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2023
Same author

Brexit and UK market exclusivities.

Pharmaceutical patent analyst·2018
Same author

Humira<sup>®</sup>: recent developments.

Pharmaceutical patent analyst·2017
Same author

Enbrel and etanercept biosimilars: a tale of two patent systems.

Pharmaceutical patent analyst·2017
Same author

Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Expert opinion on investigational drugs·2016
Same author

Humira: the impending patent battles over adalimumab biosimilars.

Pharmaceutical patent analyst·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Biotechnology
  • Endocrinology
  • Pharmacology

Background:

  • SomatoKine is a recombinant fusion protein comprising insulin-like growth factor-1 (IGF-1) and its binding protein, IGFBP-3.
  • It is under development by Insmed for potential therapeutic applications.

Purpose of the Study:

  • To evaluate SomatoKine for the treatment of growth hormone insensitivity syndrome (GHIS).
  • To assess SomatoKine as an injectable insulin sensitizer for managing type 1 and type 2 diabetes in patients with insulin resistance.

Main Methods:

  • FDA granted Orphan Drug status for GHIS treatment in July 2002.
  • A Phase II clinical trial in children with GHIS was initiated in July 2002.
  • Further clinical trials for GHIS were planned for early 2003.
  • Phase II development for type 1 and type 2 diabetes was ongoing.

Related Experiment Videos

Main Results:

  • Orphan Drug status granted by the FDA for GHIS.
  • Initiation of Phase II trials for GHIS in pediatric patients.
  • Planned expansion of clinical development into diabetes management.

Conclusions:

  • SomatoKine shows promise for treating GHIS, evidenced by Orphan Drug status and ongoing trials.
  • The drug is being explored as a novel injectable insulin sensitizer for diabetes management.